Clinical trials in Utrecht – page 116

1 973 clinical trials in Utrecht, The Netherlands across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Utrecht at a glance

1 973

clinical trials

Research sites5

Quick filters

1 973 trials in Utrecht

Open in trial search

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Doxorubicin Hydrochloride
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Encephalitis autoimmune

Not recruiting

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Neuromyelitis optica spectrum disorder

Not recruiting

Study on Imlifidase for Treating Acute Inflammation in Patients with Neuromyelitis Optica Spectrum Disorder

Registered drugNo placebo

Study on Imlifidase for Treating Acute Inflammation in Patients with Neuromyelitis Optica Spectrum Disorder

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Imlifidase
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Radboud universitair medisch centrum Stichting

Contact Research Centre

Vulval cancer+1

Not recruiting

Study of Pembrolizumab for Patients with Vulvar Squamous Cell Carcinoma

Registered drugNo placebo

Study of Pembrolizumab for Patients with Vulvar Squamous Cell Carcinoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Leids Universitair Medisch Centrum (LUMC)

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Study on the Safety and Effectiveness of Binimetinib, Lapatinib, and Vinorelbine for Patients with RAS-Mutated Metastatic Colorectal Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of Binimetinib, Lapatinib, and Vinorelbine for Patients with RAS-Mutated Metastatic Colorectal Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Binimetinib
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Dilated cardiomyopathy

Not recruiting

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:AB-1002
Sponsor:Askbio Inc.

Contact Research Centre

Encephalopathy neonatal+1

Not recruiting

Study on the Effect of Allopurinol and Hypothermia for Newborns with Hypoxic-Ischemic Encephalopathy

Registered drug

Study on the Effect of Allopurinol and Hypothermia for Newborns with Hypoxic-Ischemic Encephalopathy

Registered drug

The Netherlands

Participants:0–17 years
Substances:Allopurinol Sodium
Sponsor:Universitaetsklinikum Tuebingen AöR

Contact Research Centre

Burkitt's lymphoma

Not recruiting

Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

Registered drugNo placebo

Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer+1

Not recruiting

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Alpelisib
Sponsor:BOOG Study Center B.V.

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Eosinophilic oesophagitis

Not recruiting

Study on the Effects of EP-104IAR and Tetracosactide for Adults with Eosinophilic Esophagitis

Registered drugNo placebo

Study on the Effects of EP-104IAR and Tetracosactide for Adults with Eosinophilic Esophagitis

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Tetracosactide
Sponsor:Eupraxia Pharmaceuticals Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Utrecht

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on TTR amyloidosis and heart disease treatments, investigating new therapeutic approaches for cardiac conditions. Clinical trials evaluate novel medications for improving patient mobility and cardiac function.

Heart Disease Management
Cardiac Biomarkers
Treatment Efficacy

Research aims to enhance quality of life for patients with hereditary and wild-type ATTR cardiomyopathy.

02 Cancer Research

Comprehensive studies in gastric cancer, bladder cancer, and neuroblastoma, exploring innovative treatment combinations and diagnostic methods.

Immunotherapy Applications
Targeted Therapies
Diagnostic Imaging

Advanced trials combining established treatments with novel approaches to improve patient outcomes.

03 Neurological Disorders

Groundbreaking research in Amyotrophic Lateral Sclerosis and chronic inflammatory conditions, focusing on innovative treatments and disease modification strategies.

Gene-Targeted Therapies
Neurological Function
Disease Progression

Studies aim to develop effective treatments for rare and challenging neurological conditions.

Back to the Netherlands All countries